Home › Leukemia › Massachusetts
Pag-aaral pangklinika para sa Leukemia sa Massachusetts
28 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa Massachusetts.
Mga Lungsod sa Massachusetts
Opisyal na teksto ng pag-aaral (English)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07439211Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 2
Edad 18 hanggang 51 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT05475925Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT06138587A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT04024761A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 28, 2026 · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 21, 2026 · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Abr 6, 2026 · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 25, 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 11, 2026 · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2025 · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2025 · NCT06487247Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.